GGrantIndex
Sort

64,565 grants matching drug discovery

Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia

$999,509
Christie G. Brouillette · University Of Alabama At Birmingham · U01 · FY2010 · AI

Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

$999,501
Upendra Marathi · 7 Hills Pharma, Llc · R42 · FY2018 · CA

Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes

$999,480
Ward Peterson · Symberix, Inc. · R44 · FY2020 · CA

Isolating novel actinomycetes for antibiotic discovery

$999,461
Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2010 · AI

Coordinate Regulation of Virulence in Vibrio Cholerae

$999,436
John J Mekalanos · Harvard Medical School · R37 · FY2025 · AI

Oocyte factors for reprogramming to pluripotency

$999,388
Renee A Reijo Pera · Stanford University · RC1 · FY2010 · HD

Preventing and treating RSV pneumonia in immunocompromised cancer patients

$999,372
Brenton Scott · Pulmotect, Inc · R44 · FY2016 · HL

Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub

$999,362
Peter J Davies · Texas A&M University Health Science Ctr · U01 · FY2023 · GM

Isolating novel fungi for antibiotic discovery

$999,356
Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2010 · AI

Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis

$999,327
Brett E Crawford · Zacharon Pharmaceuticals, Inc. · R44 · FY2011 · NS

Genomic Studies of the Impact of External Factors on Parasite Development and Disease Outcome

$999,314
Joana Carneiro Da Silva · University Of Maryland Baltimore · U19 · FY2020 · AI

Isolating novel fungi for antibiotic discovery

$999,313
Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2012 · AI

Isolating novel actinomycetes for antibiotic discovery

$999,308
Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2009 · AI

Parallelized Imaging and Automated Analysis of Zebrafish Assays with a Gigapixel Microscope

$999,300
Mark Harfouche · Ramona Optics, Inc. · R44 · FY2021 · OD

Pre-clinical development of NGP 555 for the prevention of AD

$999,249
William T Comer · Neurogenetic Pharmaceuticals, Inc. · U44 · FY2014 · NS

The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship

$999,194
Paula J Bates · University Of Louisville · U01 · FY2015 · HL

The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship

$999,194
Paula J Bates · University Of Louisville · U01 · FY2016 · HL

Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT

$999,103
Douglas J Kawahara · Elex Biotech, Llc · R44 · FY2019 · HL

Therapeutic Development of Antimicrobial Biomimetics

$999,095
Richard W Scott · Polymedix, Inc, · R44 · FY2006 · AI

Preclinical development of teixobactin, a new antibiotic

$999,040
Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2018 · AI

Research and Development to Establish a Small Animal Model as a Significant Resource of High-Value Single-Domain Antibodies

$998,985
Milen Kirilov · Ingenious Targeting Laboratory, Inc. · R44 · FY2022 · AI

Therapeutic Development of Antimicrobial Biomimetics

$998,970
Richard W Scott · Polymedix, Inc, · R44 · FY2007 · AI

Novel therapy for Fragile X syndrome

$998,958
Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2021 · MH

Biomarker Quantitation by NP-MS Tissue Imaging.

$998,797
John Albert Schultz · Ionwerks, Inc. · R44 · FY2014 · DA

Biomarker Quantitation by NP-MS Tissue Imaging.

$998,797
John Albert Schultz · Ionwerks, Inc. · R44 · FY2015 · DA